Study guide
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape
Key Takeaways Explain This Topic AI
Tobacco use disorder carries 8% of the CARN-AP blueprint, roughly 11 to 13 items, despite being the substance APRNs reported spending the least clinical time on.
Smoking prevalence among people with a substance use disorder or serious mental illness remains several times the general-population rate, and tobacco-related disease kills more people in addiction treatment than the drug that brought them there.
Nicotine salt formulations in modern pods deliver high nicotine concentrations with reduced throat harshness, enabling rapid, high-dose absorption particularly in adolescents.
EVALI was traced primarily to vitamin E acetate in illicit THC-containing vaping products, not to nicotine e-liquids.
Menthol lowers the sensory harshness of smoke, increases initiation in adolescents, and is associated with lower quit success, which underlies regulatory attention to menthol products.
Last updated: September 2026
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape
Quick Answer: Nicotine is an agonist at alpha-4 beta-2 nicotinic acetylcholine receptors on ventral tegmental area dopamine neurons. Inhaled nicotine reaches the brain in 10 to 20 seconds , producing a dopamine surge, then rapid receptor desensitization and compensatory upregulation of receptor density . Nicotine's elimination half-life is about 2 hours , so upregulated receptors resensitize repeatedly through the day, generating the withdrawal-craving cycle that makes cigarettes among the most reinforcing drugs known. Tobacco use disorder is 8% of the CARN-AP blueprint.
1. Why Tobacco Is Under-Treated in Addiction Settings
The 2025 ANCB practice analysis found the mean share of APRN time spent with tobacco-using patients fell from 10.09% to 4.88% — yet the Task Force deliberately kept the blueprint weight at 8% . That gap is the point: tobacco is under-addressed in addiction practice relative to the harm it causes.
Smoking prevalence among people in substance use treatment and people with serious mental illness remains several times the general adult rate.
Tobacco-related disease is a leading cause of death among people who enter treatment for alcohol or other drug use disorders — often exceeding deaths from the index substance.
The persistent myth that treating tobacco destabilizes recovery from other substances is contradicted by the evidence : concurrent tobacco treatment during addiction treatment is associated with improved , not worsened, abstinence from alcohol and other drugs.
2. Receptor Pharmacology
Step Event Clinical consequence
Inhalation Arterial nicotine bolus reaches brain in 10 to 20 seconds Extremely tight pairing of the act of smoking with reward — the basis of powerful cue conditioning
Binding Agonism at alpha-4 beta-2 nAChRs on VTA dopamine neurons Dopamine release in nucleus accumbens
Desensitization Receptors enter a desensitized state within minutes Diminishing effect across the day; the first cigarette of the morning is the most reinforcing
Upregulation Chronic exposure increases nAChR density substantially More receptors available to signal deprivation when nicotine falls
Resensitization As nicotine clears (half-life about 2 hours), receptors return to a responsive unliganded state Craving, irritability, and the drive to redose roughly every 1 to 2 hours
This pharmacology explains two clinical facts: time to first cigarette is the single best bedside marker of dependence severity, and around-the-clock basal dosing (the patch) plus on-demand dosing (gum, lozenge, inhaler, spray) outperforms either alone.
3. The Product Landscape
Product Nicotine delivery Key clinical points
Combustible cigarettes Fastest arterial delivery Harm is driven by combustion products, not nicotine itself — an essential teaching distinction
Menthol cigarettes Same as above, with cooling/anesthetic sensory effect Reduces harshness, increases youth initiation, associated with lower quit rates; disproportionately marketed to Black communities
Cigars, little cigars, cigarillos Variable Often mistakenly seen as safer; frequently used to roll cannabis (blunts)
Smokeless (moist snuff, chew) Slower buccal absorption, high total daily dose Oral leukoplakia, gingival recession, oral and pancreatic cancer risk
Nicotine pouches Buccal, no tobacco leaf Lower cancer risk than smokeless tobacco; dependence risk remains
Heated tobacco products Heats rather than burns tobacco Reduced some toxicants; not established as a cessation aid
E-cigarettes / vaping (freebase) Slower than cigarettes Early-generation devices delivered nicotine inefficiently
Nicotine-salt pod systems High concentration with reduced harshness Enables very high nicotine intake, especially in adolescents; a single pod can approximate a pack of cigarettes in nicotine content
EVALI
E-cigarette or vaping product use-associated lung injury (EVALI) produced a cluster of severe acute lung injury cases. Investigation implicated vitamin E acetate , used as a cutting agent in illicit THC-containing vaping products , as the primary culprit — not commercial nicotine e-liquids. The correct teaching is specific: avoid informally sourced THC vaping cartridges. Presentations include dyspnea, cough, fever, gastrointestinal symptoms and bilateral infiltrates, and EVALI is a diagnosis of exclusion after infection is ruled out.
4. Biochemical Verification
Marker Half-life Window Notes
Exhaled carbon monoxide Roughly 4 to 6 hours Same-day combustible use Does not detect vaping, smokeless tobacco or NRT because none involve combustion
Cotinine 16 to 20 hours About 3 to 4 days Detects all nicotine sources including NRT, so it cannot verify abstinence in someone using NRT
Anabasine / anatabine Variable Days Tobacco alkaloids absent from pharmaceutical NRT; used to confirm tobacco abstinence in patients on NRT, notably in transplant programs
Exam trap: a patient on the nicotine patch will have a high cotinine level. Using cotinine to accuse that patient of continued smoking is a classic error; exhaled CO or anabasine is the correct test.